Moderna, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDModerna, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 94), indicating clear outperformance against the broad market. Earnings contraction of 17% provides fundamental context to the price action. However, price is extended 31% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $45.42 | +17.95% | ABOVE |
| 50 SMA | $41.03 | +30.56% | ABOVE |
| 100 SMA | $33.61 | +59.40% | ABOVE |
| 150 SMA | $31.19 | +71.74% | ABOVE |
| 200 SMA | $30.54 | +75.42% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MRNA in an uptrend right now?
MRNA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, MRNA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is MRNA overbought or oversold?
MRNA's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is MRNA outperforming the market?
MRNA has a Relative Strength (RS) Rating of 94 out of 99. Yes, MRNA is a market leader, outperforming 94% of all stocks over the past 12 months.
Where is MRNA in its 52-week range?
MRNA is trading at $53.57, which is 97% of its 52-week high ($55.20) and 95% above its 52-week low ($22.28).
How volatile is MRNA?
MRNA has a Beta of 1.25 and 52-week volatility of 66%. It's more volatile than the S&P 500 - expect bigger swings.